Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

por Ehninger, A, Kramer, M, Röllig, C, Thiede, C, Bornhäuser, M, von Bonin, M, Wermke, M, Feldmann, A, Bachmann, M, Ehninger, G, Oelschlägel, U
Publicado 2014

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

por Platzbecker, U, Wermke, M, Radke, J, Oelschlaegel, U, Seltmann, F, Kiani, A, Klut, I-M, Knoth, H, Röllig, C, Schetelig, J, Mohr, B, Graehlert, X, Ehninger, G, Bornhäuser, M, Thiede, C
Publicado 2012

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

por Kayser, S, Benner, A, Thiede, C, Martens, U, Huber, J, Stadtherr, P, Janssen, J W G, Röllig, C, Uppenkamp, M J, Bochtler, T, Hegenbart, U, Ehninger, G, Ho, A D, Dreger, P, Krämer, A
Publicado 2016

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

por Platzbecker, U, Braulke, F, Kündgen, A, Götze, K, Bug, G, Schönefeldt, C, Shirneshan, K, Röllig, C, Bornhäuser, M, Naumann, R, Neesen, J, Giagounidis, A, Hofmann, W-K, Ehninger, G, Germing, U, Haase, D, Wermke, M
Publicado 2013

Karyotype complexity and prognosis in acute myeloid leukemia

por Stölzel, F, Mohr, B, Kramer, M, Oelschlägel, U, Bochtler, T, Berdel, W E, Kaufmann, M, Baldus, C D, Schäfer-Eckart, K, Stuhlmann, R, Einsele, H, Krause, S W, Serve, H, Hänel, M, Herbst, R, Neubauer, A, Sohlbach, K, Mayer, J, Middeke, J M, Platzbecker, U, Schaich, M, Krämer, A, Röllig, C, Schetelig, J, Bornhäuser, M, Ehninger, G
Publicado 2016